ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes

• Published in: Diabetes, obesity & metabolism Vol. 23; no. 4; pp. 961 - 970
• Main Authors: Andersen, Grit, Meiffren, Grégory, Famulla, Susanne, Heise, Tim, Ranson, Aymeric, Seroussi, Cyril, Eloy, Rosy, Gaudier, Martin, Charvet, Richard, Chan, You‐Ping, Soula, Olivier, DeVries, J. Hans
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-04-2021; Wiley Subscription Services, Inc
• Subjects: Acetaminophen; Adverse events; Amylin; Analgesics; antidiabetic drug; Antidiabetics; Blood glucose; clinical trial; Diabetes; Diabetes mellitus (insulin dependent); Dosage; Gastric emptying; Glucagon; Glucose; Insulin; insulin therapy; Pharmacodynamics; Pharmacokinetics; type 1 diabetes; clinical trial; antidiabetic drug; glucagon; type 1 diabetes; insulin therapy; pharmacodynamics
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.14302

Aim
To compare the safety, pharmacokinetics and pharmacodynamics of ADO09 with insulin lispro (Lispro) and separate subcutaneous injections of human insulin and pramlintide (Ins&Pram) in 24 subjects with type 1 diabetes.
Methods
At three dosing visits, participants received single doses of ADO09, Ins&Pram or Lispro immediately before eating a standardized mixed meal together with 1 g of acetaminophen, which was used as a surrogate marker to evaluate the kinetics of gastric emptying. Premeal blood glucose was adjusted to 126 mg/dL ± 10% by means of insulin and glucose infusions. The insulin dose was 7.5 U and the pramlintide dose was 45 μg. Blood glucose, glucagon and acetaminophen concentrations were assessed as pharmacodynamic endpoints; insulin and pramlintide concentrations were analysed as pharmacokinetic endpoints, and safety and tolerability were assessed.
Results
Compared with Lispro, ADO09 reduced postprandial blood glucose (ppBG) excursions by more than 95% in the first hour postmeal (mean ± SD ∆AUC BG 0‐1 h: 1.4 ± 9.9 mg*h/dL vs. 43.5 ± 15.3 mg*h/dL; p < .0001). Maximum ppBG was significantly improved with ADO09 (∆BGmax 87.0 ± 35.5 mg/dL) versus both Lispro (109.2 ± 31.1 mg/dL; p = .0133) and Ins&Pram (109.4 ± 44.3 mg/dL; p = .0357). Gastric emptying with ADO09 was similar to Ins&Pram and significantly slower than with Lispro. All treatments were well tolerated and both adverse events and hypoglycaemic events were rare during the meal test procedure.
Conclusion
ADO09 was well tolerated and markedly reduced ppBG compared with Lispro. ADO09 formulation was generally similar to the separate administration of insulin and pramlintide, except for a better BG level in the 4‐8 h interval postmeal. These positive results warrant further investigations with ADO09.